Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Sales Volume, ASP & Number of Procedure Conducted by Procedure Type & Application The global sacral nerve stimulation market will witness a robust CAGR of 14.07%, valued at $3.27 billion in 2021, expected to appreciate and reach $10.70 billion by 2030, confirms Strategic Market Research. Sacral nerve stimulation (SNS) is a medical and electrical stimulation therapy that entails implanting a programmable stimulator under the skin, delivering low-amplitude electrical stimulation to the sacral nerve via a lead, which is commonly used to access the S3 foramen. SNS is a therapeutic approach for treating patients' bladder and bowel disorders such as overactive bladder, fecal incontinence, and bowel management. Sacral nerve stimulation helps to restore the critical functions of the bladder or bowel. According to the bladder and bowel community, it has been used to treat 200,000 patients worldwide. The treatment primarily aims to improve bladder and brain coordination. Moreover, sacral nerve stimulation is a highly successful and safe treatment for fecal and urinary problems. According to the Centres for Medicare and Medicaid Services, urinary incontinence affects around 13 million adults in the U.S., and women constitute the majority of participants. In addition, women are more likely to experience urine incontinence than men. A study published in March 2021 by SedigheBatmani et al. in the BMC Geriatrics Journal indicates that the highest prevalence of urine incontinence was recorded in older adult women in Asia (45.1 percent). According to the National Institute of Health, the general 5-year and 7-year SNM success rates were 75.1% and 69.8%, respectively. Covid-19 Impact The COVID-19 outbreak negatively impacted the market, as most Non-COVID treatment services were paused to free up the healthcare centers for COVID-19-infected patients and reduce the transmission of the SARS-CoV-2 virus. The British Journal of Surgery published a report in May 2020 detailing, During COVID-19 in 2020, 28.4 million elective procedures were canceled or postponed over 12 weeks due to peak in-hospital service disruptions. Jeremy Yuen-Chun Teoh et al. conducted a global survey titled "A Global Survey on the Impact of COVID-19 on Urological Services" (2020). According to the study, the pandemic had the highest impact on outpatient clinics treating women's urinary incontinence, benign prostatic hyperplasia, infertility, benign scrotal conditions, renal stone, and bladder stone. Furthermore, during the COVID-19 pandemic, 28 percent of all outpatient clinics, 30 percent of all outpatient investigations and procedures, and 31 percent of all urological surgeries experienced a delay of more than eight weeks. Therefore, the COVID-19 pandemic is expected to negatively influence the market due to the circumstances mentioned above. Key Industry Drivers: The increasing number of patients for various diseases such as overactive bladder disorders, urge incontinence, etc., along with increasing investment in research and development of technological products, are set to drive the market The increasing elderly population and cases related to obesity, diabetes, hypertension, and smoking influence urine incontinence in older women and tend to drive the market's growth. Hence, with the rise in the target patients in the coming years, it is highly possible to increase the demand for this market. Moreover, the market is likely to be driven by the growing geriatric population globally, increasing research investments, and technical improvements related to creating novel medical devices over the forecasted period. The primary drivers of market expansion are the increasing occurrence of overactive bladder disorders, urge incontinence, such as urinary tract infections, and the rising number of patients suffering from OAB and fecal incontinence. The Indian Journal of Community Medicine published an article in 2019 that says that the prevalence of urinary incontinence in postmenopausal women aged 45 to 90 years was around 26.47%. In addition, the National Center for Biotechnology Information (NCBI) stated in an article titled "Urinary Incontinence in Postmenopausal Women" (2019) that various diseases have been increasing around the world, including Parkinson's disease, diabetes, and multiple sclerosis, which may lead to an increased prevalence of urinary incontinence. Restraint - Adverse Government Policies and Side Effects of Nerve Stimulation will Restrain the Market's Growth. The market's expansion is hampered by health hazards connected with nerve stimulation and adverse governmental policies. Moreover, the high costs associated with the treatment procedures will operate as a market growth barrier. Concerns about the device's adverse and side effects will further derail the growth rate of the sacral nerve stimulation (SNS). Opportunity - Untapped Regions with Greater Medical Needs and Growing Elderly Population Worldwide will Create Several Market Opportunities. The market expansion is likely to succeed in untapped regions with unmet medical needs and technology improvements to minimize the associated infections. The growing senior population will open up the new business potential for lung cancer screening programs. Urinary tract infections (UTIs) were the most prevalent outpatient infections, according to a study published in Therapeutic Advances in Urology (2019). UTIs were exceptionally high among the elders, with 205 women aged 65 and above having UTIs, accounting for 11% of the total population investigated. These populations will likely boost the segment's expansion by creating a demand for the therapy. Market Analysis Of Different Segments Covered in the Report By Product External Implantable By Application Urge Incontinence Chronic Anal Fissure Urinary &Fecal Incontinence Others Regional Coverage Analysis North America U.S Canada Mexico Europe Germany France Italy Switzerland U.K. Rest of Europe Asia-Pacific Japan China India Rest of Asia-Pacific LAMEA Brazil Israel South Africa Saudi Arabia Rest of LAMEA Product Analysis & Insights The implantable devices segment of the sacral nerve stimulation (SNS) market is expected to experience considerable growth during the forecasted period. These devices greatly enhance patients' quality of life by providing long-term relief from ailments including fecal and urine incontinence. Implantable SNS device adoption is further fueled by higher spending on healthcare, better infrastructure for healthcare delivery, and increased patient and professional knowledge of the advantages of SNS therapy, particularly in emerging markets. Application Analysis & Insights The urinary and fecal incontinence segment ruled the sacral nerve stimulation market due to the high incidence of these disorders and their substantial influence on patients' quality of life. The prevalence of incontinence diseases rises with rising aging population, creating a need for efficient treatment options. Furthermore, the increasing recognition and progress in SNS technology encourage the growth of this market. Regional Analysis & Insights North America holds the largest Sacral Nerve Stimulation Market share and is expected to expand due to the growing geriatric population and the growing desire for minimally invasive operations. According to the Population Reference Bureau's "Aging in the United States, "As of 2018, there were 52 million Americans aged 65 or older. By 2060, the number is expected to reach 95 million. Also, Urinary incontinence is predicted to impact 10-13 million people in the United States, according to a Medscape article published in June 2021. Also, Constipation is very frequent in the United States, affecting people of all ages and populations. Constipation affects around 16 out of every 100 people, in which 33 out of every 100 individuals are 60 years and above in age. Moreover, functional Constipation was found lowest in Australia, followed by China, Germany, and Honduras. At the same time, South Korea possesses the most cases, followed by Turkey, the Netherlands, and Ghana. The Asia Pacific will be growing fastest from 2020 to 2028 due to the increased number of patients suffering from fecal and urine incontinence. Sacral Nerve Stimulation Market Report Coverage Report Attribute Details Forecast Period 2021 - 2030 The market size value in 2021 USD 3.27 Billion The revenue forecast in 2030 USD 10.70 Billion Growth rate CAGR of approximately 14.07% The base year for estimation 2021 Historical data 2017 – 2020 Unit USD Billion, CAGR (2021 - 2030) Segmentation By Product, By Application, By Region. By Product External, Implantable. By Application Urge Incontinence, Chronic Anal Fissure, Urinary &Fecal Incontinence, Others. By Region North America, Europe, Asia Pacific, Australian Bureau of Statistics. Country Scope U.S., Canada, France, Germany, the U.K., China, Japan, India, South Korea, Mexico, Brazil, U.A.E., etc. Company Usability Profiles Cyberonics, Codman & Shurtleff, Axonics Modulation Technologies, NeuroPace, Medtronic, Uroplasty, Laborie, St. Jude Medical, Synapse Biomedical, IntraPace, Boston Scientific Corporation, Nevro Corp. Pricing and purchase options Avail of customized purchase options to meet your exact research needs. Sacral Nerve Stimulation Market Competitive Landscape Analysis Key Players in the market are as follows: Cyberonics Codman & Shurtleff Axonics Modulation Technologies NeuroPace Medtronic Uroplasty Laborie St. Jude Medical Synapse Biomedical IntraPace Boston Scientific Corporation Nevro Corp. Recent Developments In August 2023, The US Food and Drug Administration (FDA) has approved a De Novo marketing request for BlueWind Medical, Ltd.'s revolutionary tibial neuromodulation therapy, the Revi System, which treats urgency incontinence symptoms either on their own or in conjunction with urine urgency. Before patients fail or are unable to tolerate more conservative medication, doctors should use their judgment to assess if Revi can be used. Based on findings from the OASIS pivotal trial, where Revi showed statistically significant improvement in the decrease of UUI symptoms compared to baseline and a satisfactory safety profile, the De Novo award is for men and women with urge urine incontinence (UUI). In January 2024, Boston Scientific, a major player in the medical device industry, announced that it will pay $3.7 billion to acquire Axonics, a manufacturer of neurostimulation devices used to treat bowel and urine dysfunction, adding to its impressive list of recent acquisitions. It is also believed that Boston Scientific's urology division will profit from this transaction. Frequently Asked Question About This Report Who are the key players operating in the market? The key players in the market are Cyberonics, Codman & Shurtleff, Axonics Modulation Technologies, NeuroPace, Medtronic, Uroplasty, Laborie, St. Jude Medical, Synapse Biomedical, IntraPace, Boston Scientific Corporation, Nevro Corp. What do you mean by interstitial Cystitis? Interstitial Cystitis is a chronic pain disorder that can cause pressure in the bladder, pain in the bladder, and sometimes pain in the pelvis. Which region has the largest market share? North America has the largest market share. How big is the sacral nerve stimulation market? The global sacral nerve stimulation market size was $3.27 Bn in 2021 and is predicted to reach $10.70 Bn by 2030, with a CAGR of 14.07%. What is the sacral nerve stimulation market growth? The global sacral nerve stimulation market is expected to grow at a compound annual growth rate (CAGR) of 14.07% from 2021 to 2030 to reach USD10.70 billion by 2030. Sources https://www.bladderandbowel.org/surgical-treatment/sacral-nerve-stimulation/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3060785/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6326196/ https://pubmed.ncbi.nlm.nih.gov/31728086/ https://emedicine.medscape.com/article/452289-overview Chapter 1. Introduction 1.1 Study Objectives 1.2 Market Definition Table 1 Inclusions and Exclusions 1.3 Study Scope 1.3.1 Markets Covered Figure 01: Market Segmentation 1.3.2 Geographic Scope Figure 02: Market Geography covered 1.3.3 Years Considered 1.4 Stakeholders Chapter 2. Research Methodology 2.1 Data Procurement 2.2 Paid Database 2.2.1 Secondary Data 2.2.1.1 Key Secondary sources 2.2.2 Primary Data 2.2.2.1 Primary sources 2.2.2.2 Key industry insights 2.2.2.3 Primary interviews with experts 2.2.2.4 Key primary respondent list 2.3 Market Size Estimation 2.4 Bottom-Up and Top-Down Approaches 2.4.1 Bottom-Up Approach 2.4.1.1 Approach for arriving at market size by bottom-up analysis Figure 03: Market: Bottom-Up Approach 2.4.2 Top-Down Approach 2.4.2.1 Approach for Capturing Market Size by Top-Down Analysis Figure 04: Market: Top-Down Approach 2.5 Market Breakdown and Data Triangulation Figure 05: Data Triangulation 2.6 Research Methodology 2.7 Risk Assessment Table 2: Risk Assessment Chapter 3. Executive Summary 3.1 Market: Post-Covid-19 Figure 06: Impact of Covid-19 on Market 3.1.1 Actual Scenario Figure 07: Realistic Scenario: Market, 2020–2028 (USD Million) 3.1.2 Pessimistic Scenario Figure 08: Pessimistic Scenario: Market, 2020–2028 (USD Million) 3.1.3 Optimistic Scenario Figure 09: Optimistic Scenario: Market, 2020–2028(USD Million) 3.1.4 Market Summary Figure 10: External SNS to Witness Highest CAGR in the Market, By Product, During Forecast Period Figure 11: Urinary and fecal incontinence Higher CAGR in the Market for Application Segment during Forecast Period Figure 12: North America to Account for Largest Share of Global Market In 2020 Chapter 4. Market Definitions 4.1 Market Segmentation Figure 13: Market Segmentation Chapter 5. Industry Outlook 5.1 Market Snapshot 5.2 Global Sacral Nerve Stimulation Market 5.2.1 Global market, 2020 – 2028 (USD Million) 5.3 Regional Segment Analysis 5.3.1 Global market, by region, 2021-2030 (USD Million) 5.4 Product Segment Analysis 5.4.1 Global market, By Product, 2021-2030 (USD Million) 5.5 Application Segment Analysis 5.5.1 Global market, By Application, 2021-2030 (USD Million) 5.6 Value Chain Analysis 5.7 Market Variable Analysis 5.7.1 Market Drivers Analysis 5.7.2 Market Restraints Analysis 5.8 Business Environment Analysis Tool 5.8.1 market PEST analysis 5.8.2 market Porter’s analysis 5.9 Penetration & Growth Prospect Mapping Chapter 6. Market Overview 6.1 Introduction 6.2 Market Dynamics Figure 14 Market: Drivers, Restraints, Opportunities, and Challenges 6.2.1 Drivers Figure 15 Market Drivers and Their Impact 6.2.2 Restraints Figure 16 Market Restraints and Their Impact 6.2.3 Opportunities Figure 17 Market Opportunities and Their Impact 6.2.4 Challenges Figure 18 Market Challenges and Their Impact 6.3 Impact of Covid-19 on Market 6.4 Value Chain Analysis Figure 19 Value Chain Analysis: Market 6.5 Ecosystem Figure 20 Market: Ecosystem Table 3 Market: Ecosystem Figure 21 Revenue Shift in Market 6.6 Patent Analysis Table 4 Number of Patents Registered in Market in USA in Last 9 Years Figure 22 Top 12 Companies with Highest No. of Patents in Last 9 Years Figure 23 No of Patents Granted Per Year, 2019–2020 Table 5 List of Global Patents in Market 6.7 Trade Analysis Figure 24 Import Data for External, By Country, 2016–2020 (USD Thousand) Table 6 Import Data for Implantable, By Country, 2016–2020 (USD Thousand) Figure 25 Export Data for External, By Country, 2016–2020 (USD Thousand) Table 7 Export Data for Implantable, By Country, 2016–2020 (USD Thousand) 6.8 Tariff Analysis 6.9 Case Study Analysis 6.10 Porter’s Five Forces Analysis Table 8 Market: Porter’s Five Forces Analysis, 2020 6.10.1 Threat of New Entrants 6.10.2 Threat of Substitutes 6.10.3 Bargaining Power of Buyers 6.10.4 Bargaining Power of Suppliers 6.10.5 Degree of Competition 6.11 Technology Analysis 6.11.1 Trends in Technology (2014-2020) 6.11.2 Trends in Technology (2021-2028) Table 9 Key Regulations: Market 6.12 Pricing Analysis 6.12.1 Average Price Trend Analysis (By region, By Countries) Chapter 7. Competitive & Vendor Landscape 7.1 Company Market Share Analysis Table 10: Key Players market share Figure 26: Key players market share of companies 7.2 Manufacturers Manufacturing Sites, Area Served, Product Type 7.3 Market Competitive Situation and Trends 7.4 Manufacturers Mergers & Acquisitions, Expansion Plans Chapter 8. Global Market: Product Segment Analysis 8.1 Introduction 8.2 Sales Volume & Revenue Analysis (2021-2030) Table 11 Market, By Product, 2021–2028 (USD Million) Figure 27 Market, By Product Figure 28 External SNS Segment to Register Highest CAGR in Market During Forecast Period 8.3 External 8.3.1 External market, 2021-2030 (USD Million) Figure 29: External market, 2021-2030 (USD Million) 8.4 Implantable 8.4.1 Implantable market, 2021-2030 (USD Million) Figure 30: Implantable market, 2021-2030 (USD Million) Chapter 9. Global Market: Application Segment Analysis 9.1 Introduction 9.2 Sales Volume & Revenue Analysis (2021-2030) Table 12: Market, By Application, 2021–2028 (USD Million) Figure 31: Market, By Application, 2021–2028 (USD Million) Figure 32: urinary and fecal incontinence Segment to Register Highest CAGR in Market during Forecast Period 9.3 Urge Incontinence 9.3.1 Urge Incontinence market, 2021-2030 (USD Million) Figure 33: Urge Incontinence market, 2021-2030 (USD Million) 9.4 Chronic Anal Fissure 9.4.1 Chronic Anal Fissure market, 2021-2030 (USD Million) Figure 34: Chronic Anal Fissure market, 2021-2030 (USD Million) 9.5 Urinary & Fecal Incontinence 9.5.1 Urinary & Fecal Incontinence market, 2021-2030 (USD Million) Figure 35: Urinary & Fecal Incontinence market, 2021-2030 (USD Million) 9.6 Others 9.6.1 Others market, 2021-2030 (USD Million) Figure 36: Others market, 2021-2030 (USD Million) Chapter 10. Global Market: Regional Outlook 10.1 North America Figure 37: North America Market, By Revenue Forecast (2021-2030) 10.1.1 North America market, by country, 2021-2030 (USD Million) Table 13: North America Market, by Country, 2021-2030 Figure 38: North America Market 10.1.2 North America market, By Product, 2021-2030 (USD Million) Table14: North America market, By Product, 2021-2030 (USD Million) Figure 39: North America market, By Product, 2021-2030 (USD Million) 10.1.3 North America market, by Application, 2021-2030 (USD Million) Table 15: North America market, by Application, 2021-2030 (USD Million) Figure 40: North America market, by Application, 2021-2030 (USD Million) 10.1.4 U.S. 10.1.4.1 U.S. market, By Product, 2021-2030 (USD Million) Figure 41: U.S. market, By Product, 2021-2030 (USD Million) 10.1.4.2 U.S. market, by Application, 2021-2030 (USD Million) Figure 42: U.S. market, by Application, 2021-2030 (USD Million) 10.1.5 Canada 10.1.5.1 Canada market, By Product, 2021-2030 (USD Million) Figure 43: Canada market, By Product, 2021-2030 (USD Million) 10.1.5.2 Canada market, by Application, 2021-2030 (USD Million) Figure 44: Canada market, by Application, 2021-2030 (USD Million) Figure 45: Canada market, by Application, 2021-2030 (USD Million) Figure 46: Canada market, by Application, 2021-2030 (USD Million) 10.2 Europe Figure 47: Europe Market, By Revenue Forecast (2021-2030) 10.2.1 Europe market, by country, 2021-2030 (USD Million) Table 16: Europe market, by country, 2021-2030 (USD Million) Figure 48: Europe market, by country, 2021-2030 (USD Million) 10.2.2 Europe market, By Product, 2021-2030 (USD Million) Table 17: Europe market, By Product, 2021-2030 (USD Million) Figure 49: Europe market, By Product, 2021-2030 (USD Million) 10.2.3 Europe market, by Application, 2021-2030 (USD Million) Table 18: Europe market, by Application, 2021-2030 (USD Million) Figure 50: Europe market, by Application, 2021-2030 (USD Million) 10.2.4 U.K. 10.2.4.1 U.K. market, By Product, 2021-2030 (USD Million) Figure 51: U.K. market, By Product, 2021-2030 (USD Million) 10.2.4.2 U.K. market, by Application, 2021-2030 (USD Million) Figure 52: U.K. market, by Application, 2021-2030 (USD Million) 10.2.5 Germany 10.2.5.1 Germany market, By Product, 2021-2030 (USD Million) Figure 53: Germany market, By Product, 2021-2030 (USD Million) 10.2.5.2 Germany market, by Application, 2021-2030 (USD Million) Figure 54: Germany market, by Application, 2021-2030 (USD Million) 10.2.6 France 10.2.6.1 France market, By Product, 2021-2030 (USD Million) Figure 55: France market, By Product, 2021-2030 (USD Million) 10.2.6.2 France market, by Application, 2021-2030 (USD Million) Figure 56: France market, by Application, 2021-2030 (USD Million) 10.2.7 Rest of Europe 10.2.7.1 Rest of Europe market, By Product, 2021-2030 (USD Million) Figure 57: Rest of Europe market, By Product, 2021-2030 (USD Million) 10.2.7.2 Rest of Europe market, by Application, 2021-2030 (USD Million) Figure 58: Rest of Europe market, by Application, 2021-2030 (USD Million) 10.3 Asia Pacific Figure 59: Asia Pacific Market, By Revenue Forecast (2021-2030) 10.3.1 Asia Pacific market, by country, 2021-2030 (USD Million) Table 19: Asia Pacific market, by country, 2021-2030 (USD Million) Figure 60: Asia Pacific market, by country, 2021-2030 (USD Million) 10.3.2 Asia Pacific market, By Product, 2021-2030 (USD Million) Table 20: Asia Pacific market, By Product, 2021-2030 (USD Million) Figure 61: Asia Pacific market, By Product, 2021-2030 (USD Million) 10.3.3 Asia Pacific market, by Application, 2021-2030 (USD Million) Table 21: Asia Pacific market, by Application, 2021-2030 (USD Million) Figure 62: Asia Pacific market, by Application, 2021-2030 (USD Million) 10.3.4 China 10.3.4.1 China market, By Product, 2021-2030 (USD Million) Figure 63: China market, By Product, 2021-2030 (USD Million) 10.3.4.2 China market, by Application, 2021-2030 (USD Million) Figure 64: China market, by Application, 2021-2030 (USD Million) 10.3.5 India 10.3.5.1 India market, By Product, 2021-2030 (USD Million) Figure 65: India market, By Product, 2021-2030 (USD Million) 10.3.5.2 India market, by Application, 2021-2030 (USD Million) Figure 66: India market, by Application, 2021-2030 (USD Million) 10.3.6 Japan 10.3.6.1 Japan market, By Product, 2021-2030 (USD Million) Figure 67: Japan market, By Product, 2021-2030 (USD Million) 10.3.6.2 Japan market, by Application, 2021-2030 (USD Million) Figure 68: Japan market, by Application, 2021-2030 (USD Million) 10.3.7 South Korea 10.3.7.1 South Korea market, By Product, 2021-2030 (USD Million) Figure 69: South Korea market, By Product, 2021-2030 (USD Million) 10.3.7.2 South Korea market, by Application, 2021-2030 (USD Million) Figure 70: South Korea market, by Application, 2021-2030 (USD Million) 10.3.8 Rest of APAC 10.3.8.1 Rest of APAC market, By Product, 2021-2030 (USD Million) Figure 71: Rest of APAC market, By Product, 2021-2030 (USD Million) 10.3.8.2 Rest of APAC market, by Application, 2021-2030 (USD Million) Figure 72: Rest of APAC market, by Application, 2021-2030 (USD Million) 10.4 Latin America Figure 73: Latin America Market, By Revenue Forecast (2021-2030) 10.4.1 Latin America market, by country, 2021-2030 (USD Million) Table 22: Latin America market, by country, 2021-2030 (USD Million) Figure 74: Latin America market, by country, 2021-2030 (USD Million) 10.4.2 Latin America market, By Product, 2021-2030 (USD Million) Table 23: Latin America market, By Product, 2021-2030 (USD Million) Figure 75: Latin America market, By Product, 2021-2030 (USD Million) 10.4.3 Latin America market, by Application, 2021-2030 (USD Million) Table 24: Latin America market, by Application, 2021-2030 (USD Million) Figure 76: Latin America market, by Application, 2021-2030 (USD Million) 10.4.4 Brazil 10.4.4.1 Brazil market, By Product, 2021-2030 (USD Million) Figure 77: Brazil market, By Product, 2021-2030 (USD Million) 10.4.4.2 Brazil market, by Application, 2021-2030 (USD Million) Figure 78: Brazil market, by Application, 2021-2030 (USD Million) 10.4.5 Mexico 10.4.5.1 Mexico market, By Product, 2021-2030 (USD Million) Figure 79: Mexico market, By Product, 2021-2030 (USD Million) 10.4.5 2 Mexico market, by Application, 2021-2030 (USD Million) Figure 80: Mexico market, by Application, 2021-2030 (USD Million) 10.4.6 Rest of the Latin America 10.4.6.1 Rest of the Latin America market, By Product, 2021-2030 (USD Million) Figure 81: Rest of the Latin America market, By Product, 2021-2030 (USD Million) 10.4.6.2 Rest of the Latin America market, by Application, 2021-2030 (USD Million) Figure 82: Rest of the Latin America market, by Application, 2021-2030 (USD Million) 10.5 MEA Figure 83: MEA Market, By Revenue Forecast (2021-2030) 10.5.1 MEA market, By Product, 2021-2030 (USD Million) Figure 84: MEA market, By Product, 2021-2030 (USD Million) 10.5.2 MEA market, by Application, 2021-2030 (USD Million) Figure 85: MEA market, by Application, 2021-2030 (USD Million) Chapter 11. Competitive Landscape 11.1 Cyberonics. 11.1.1 Company overview 11.1.2 Financial performance 11.1.3 Product Portfolio Analysis 11.1.4 Business Strategy & Recent Development 11.2 Codman & Shurtleff. 11.2.1 Company overview 11.2.2 Financial performance 11.2.3 Product Portfolio Analysis 11.2.4 Business Strategy & Recent Development 11.3 Axonics Modulation Technologies. 11.3.1 Company overview 11.3.2 Financial performance 11.3.3 Product Portfolio Analysis 11.3.4 Business Strategy & Recent Development 11.4 NeuroPace. 11.4.1 Company overview 11.4.2 Financial performance 11.4.3 Product Portfolio Analysis 11.4.4 Business Strategy & Recent Development 11.5 Medtronic. 11.5.1 Company overview 11.5.2 Financial performance 11.5.3 Product Portfolio Analysis 11.5.4 Business Strategy & Recent Development 11.6 F. Uroplasty. 11.6.1 Company overview 11.6.2 Financial performance 11.6.3 Product Portfolio Analysis 11.6.4 Business Strategy & Recent Development 11.7 Laborie. 11.7.1 Company overview 11.7.2 Financial performance 11.7.3 Product Portfolio Analysis 11.7.4 Business Strategy & Recent Development 11.8 St. Jude Medical. 11.8.1 Company overview 11.8.2 Financial performance 11.8.3 Product Portfolio Analysis 11.8.4 Business Strategy & Recent Development 11.9 Synapse Biomedical. 11.9.1 Company overview 11.9.2 Financial performance 11.9.3 Product Portfolio Analysis 11.9.4 Business Strategy & Recent Development 11.10 IntraPace. 11.10.1 Company overview 11.10.2 Financial performance 11.10.3 Product Portfolio Analysis 11.10.4 Business Strategy & Recent Development